Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Mayne Pharma Group Limited    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.
Sales per Business
20192020Delta
AUD (in Million)%AUD (in Million)%
Generic Products320.7761.1%253.0555.4% -21.11%
Metrics Contract Services72.2013.7%82.8218.1% +14.71%
Specialty Brands91.5617.4%78.7617.2% -13.98%
Mayne Pharma International40.687.7%42.369.3% +4.13%
Sales per region
20192020Delta
AUD (in Million)%AUD (in Million)%
United States484.5592.3%414.6390.7% -14.43%
Australia28.345.4%28.246.2% -0.37%
Other8.871.7%9.312% +4.99%
South Korea3.450.7%4.801.1% +39.38%
Managers and Directors
NameAgeSinceTitle
Scott Richards562012Chief Executive Officer, MD & Executive Director
Roger Campbell Corbett772011Independent Non-Executive Chairman
Peter Paltoglou-2020Chief Financial Officer
Bruce L. Mathieson762007Independent Non-Executive Director
Ian Frank Scholes652007Independent Non-Executive Director
Bruce G. Robinson, Dr.632014Independent Non-Executive Director
Nancy Dolan682016Independent Non-Executive Director
Frank C. Condella662018Independent Non-Executive Director
Patrick J. Blake552018Independent Non-Executive Director
Laura Loftus--Secretary & Associate General Counsel
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,679,068,131 1,362,291,673 81.1% 0 0.0% 81.1%
Shareholders
NameEquities%
Investors Mutual Ltd. 146,034,058 8.70%
Bruce L. Mathieson 105,577,583 6.29%
Lazard Asset Management Pacific Co. 86,044,209 5.12%
Mithra Pharmaceuticals SA 83,100,000 4.95%
Dimensional Fund Advisors LP 43,954,463 2.62%
The Vanguard Group, Inc. 39,580,987 2.36%
Scott Richards 34,455,066 2.05%
APG Asset Management NV 29,660,278 1.77%
Norges Bank Investment Management 26,833,288 1.60%
Vanguard Investments Australia Ltd. 19,008,233 1.13%
Holdings
NameEquities%Valuation
Inhibitor Therapeutics, Inc. (INTI) 201,842,73954.0%7,064,496 USD
HedgePath Pharmaceuticals, Inc. 5,797,102100.0%202,899 USD
Company contact information
Mayne Pharma Group Ltd.
1538 Main North Road
Salisbury South
Salisbury, South Australia (SA) 5106

Phone : +61.8.8209.2666
Fax : +61.8.8281.0284
Web : http://www.maynepharma.com